American Well Corporation (AMWL)

NYSE: AMWL · Real-Time Price · USD
7.97
+0.22 (2.84%)
May 8, 2026, 4:00 PM EDT - Market closed
Market Cap133.17M +7.4%
Revenue (ttm)237.38M -9.3%
Net Income-87.88M
EPS-5.41
Shares Out 16.71M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume119,591
Open7.75
Previous Close7.75
Day's Range7.48 - 8.00
52-Week Range3.71 - 9.15
Beta1.53
AnalystsHold
Price Target7.30 (-8.41%)
Earnings DateMay 5, 2026

About AMWL

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Amwell Platform, a cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings; Amwell Carepoint, a device enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings; Amwell Converge, a platform and wraparound services of digital care into th... [Read more]

Sector Healthcare
IPO Date Sep 17, 2020
Employees 562
Stock Exchange NYSE
Ticker Symbol AMWL
Full Company Profile

Financial Performance

In 2025, American Well's revenue was $249.33 million, a decrease of -1.98% compared to the previous year's $254.36 million. Losses were -$95.70 million, -54.02% less than in 2024.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for AMWL stock is "Hold." The 12-month stock price target is $7.3, which is a decrease of -8.41% from the latest price.

Price Target
$7.3
(-8.41% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Amwell price target raised to $6.50 from $6 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Amwell (AMWL) to $6.50 from $6 and keeps an Equal Weight rating on the shares. Revenue upside in the quarter and tighter

2 days ago - TheFly

Amwell price target raised to $8 from $5 at TD Cowen

TD Cowen analyst Charles Rhyee raised the firm’s price target on Amwell (AMWL) to $8 from $5 and keeps a Hold rating on the shares. The firm said the company

2 days ago - TheFly

American Well Earnings Call Transcript: Q1 2026

Revenue declined 18% year-over-year in Q1 2026, but gross margin remained strong and cost discipline led to a significant reduction in losses. Renewals and pipeline growth were robust, with confidence in achieving cash flow breakeven in Q4 and multi-year growth ahead.

3 days ago - Transcripts

Amwell® Announces Results for First Quarter 2026

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results ...

3 days ago - GlobeNewsWire

Amwell® to report first quarter 2026 operating results

BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report first quarter 2026 o...

18 days ago - GlobeNewsWire

American Well Transcript: TD Cowen 46th Annual Health Care Conference

Virtual healthcare is challenged by market fragmentation, but growth is driven by payer and government segments. Major contracts like Elevance and DHA support revenue stability, with AI integration enhancing efficiency. 2026 guidance targets $195–$205M revenue and EBITDA breakeven, with strong cash reserves and new government opportunities expected.

2 months ago - Transcripts

Amwell® to Participate in Upcoming Investor Conference

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced that Mark Hirschh...

2 months ago - GlobeNewsWire

Amwell makes grant to new employee under inducement plan

BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Amwell ®  (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, announced that on February 18, A...

2 months ago - GlobeNewsWire

Amwell price target lowered to $5 from $7 at TD Cowen

TD Cowen analyst Charles Rhyee lowered the firm’s price target on Amwell (AMWL) to $5 from $7 and keeps a Hold rating on the shares. The firm said Q4 EBITDA

3 months ago - TheFly

Amwell price target lowered to $5 from $6 at Stifel

Stifel analyst David Grossman lowered the firm’s price target on Amwell (AMWL) to $5 from $6 and keeps a Hold rating on the shares. 2026 revenue guidance coming in about

3 months ago - TheFly

American Well Earnings Call Transcript: Q4 2025

2025 saw a strategic transformation to a unified tech platform, with divestitures and cost reductions leading to improved margins and a higher-quality revenue base. 2026 guidance projects lower revenue but improved profitability, with positive cash flow expected in Q4.

3 months ago - Transcripts

Amwell® Announces Results for Fourth Quarter and Full Year 2025

BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results...

3 months ago - GlobeNewsWire

Amwell® to report fourth quarter and full year 2025 operating results

BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and fu...

3 months ago - GlobeNewsWire

Amwell price target lowered to $6 from $10.50 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Amwell (AMWL) to $6 from $10.50 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm

5 months ago - TheFly

Amwell price target lowered to $7 from $10 at TD Cowen

TD Cowen lowered the firm’s price target on Amwell (AMWL) to $7 from $10 and keeps a Hold rating on the shares. The firm said its 3Q adj. EBITDA beat/raise

6 months ago - TheFly

Amwell price target lowered to $6 from $8 at Stifel

Stifel lowered the firm’s price target on Amwell (AMWL) to $6 from $8 and keeps a Hold rating on the shares. While the company’s execution on cost takeout and the

6 months ago - TheFly

American Well Earnings Call Transcript: Q3 2025

Q3 revenue and adjusted EBITDA exceeded expectations, driven by higher subscription revenue, cost efficiencies, and a shift to a more software-focused model. The company is divesting non-core assets, investing in AI, and expects positive cash flow from operations by end of 2026.

6 months ago - Transcripts

Amwell® Announces Results for Third Quarter 2025

BOSTON , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial result...

6 months ago - GlobeNewsWire

Amwell® to report third quarter 2025 operating results; company leaders to attend upcoming investor conferences

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report third quarter 2025 op...

6 months ago - GlobeNewsWire

American Well Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

The company is accelerating its shift to a technology-enabled care model, focusing on unified, AI-driven platforms and high-margin software solutions. Recent government wins, cost reductions, and a clear mission position it for growth and profitability by 2026.

8 months ago - Transcripts

Amwell makes grant to new employees under inducement plan

BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Amwell ®  (NYSE: AMWL), a leading technology-enabled care platform provider, announces that on August 8, Amwell made grants of RSUs covering an aggregate of 7...

9 months ago - GlobeNewsWire

Amwell price target lowered to $10 from $12 at TD Cowen

TD Cowen lowered the firm’s price target on Amwell (AMWL) to $10 from $12 and keeps a Hold rating on the shares. The firm updated its model following Q2 results

9 months ago - TheFly

American Well Earnings Call Transcript: Q2 2025

Q2 2025 featured strong revenue growth, margin expansion, and a key MHS contract extension, though guidance was revised lower due to government budget constraints. Cost initiatives and a focus on subscription software are driving improved EBITDA and a path to positive cash flow in 2026.

9 months ago - Transcripts

Amwell® Announces Results for Second Quarter 2025

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the seco...

9 months ago - GlobeNewsWire

Amwell awarded extension of its Digital First contract to transform MHS

Amwell (AMWL) announced that as part of a Leidos-led partnership, it has been awarded an extension of its next-generation Digital First contract to power the digital transformation of the Military

9 months ago - TheFly